National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Core Viewpoint - The National Advertising Division (NAD) is referring BridgeBio Pharma Inc. to government agencies for failing to participate in an inquiry regarding advertising claims about its product Attruby compared to Pfizer's Vyndamax [1][3]. Group 1: Company Actions - BridgeBio Pharma Inc. declined to engage in the NAD self-regulatory process, leading to the referral to appropriate government agencies [3]. - Pfizer, Inc. challenged claims made by BridgeBio regarding the superiority of Attruby over Vyndamax, citing misleading information based on FDA correspondence [2]. Group 2: Product Information - Both Pfizer and BridgeBio market prescription medications for treating transthyretin amyloid cardiomyopathy, a serious condition caused by the accumulation of transthyretin protein in the heart and other organs [2]. - The specific claims under scrutiny involve the assertion that Attruby offers greater TTR stabilization rates compared to Vyndamax [2]. Group 3: Regulatory Context - The NAD operates as part of BBB National Programs, which focuses on independent self-regulation and dispute resolution in advertising, ensuring truthfulness and fair competition [5]. - BBB National Programs has been enhancing consumer trust in business for over 50 years through various self-regulatory initiatives [4].